TY - JOUR
T1 - Mutant selection window of four quinolone antibiotics against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis
AU - Nakai, Hajime
AU - Sato, Takumi
AU - Uno, Takashi
AU - Furukawa, Emiko
AU - Kawamura, Masato
AU - Takahashi, Hiroshi
AU - Watanabe, Akira
AU - Fujimura, Shigeru
N1 - Funding Information:
Watanabe A has received speaker's honorarium from MSD K.K., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho-Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc.; donation from Astellas Pharma Inc. , Daiichi Sankyo Co., Ltd. , Sumitomo Dainippon Pharma Co., Ltd. ; and grant support from Kyorin Pharmaceutical Co., Ltd. , Shionogi & Co., Ltd. , Daiichi Sankyo Co., Ltd. , Taisho-Toyama Pharmaceutical Co., Ltd. , Taiho Pharmaceutical Co., Ltd. , Toyama Chemical Co., Ltd. , FUJIFILM Pharma Co., Ltd. and Meiji Seika Pharma Co., Ltd.
Funding Information:
Watanabe A has received speaker's honorarium from MSD K.K., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho-Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc.; donation from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd.; and grant support from Kyorin Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho-Toyama Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., FUJIFILM Pharma Co., Ltd. and Meiji Seika Pharma Co., Ltd.
Publisher Copyright:
© 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Community-acquired pneumonia and otitis media are caused by several bacterial species, including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. For the treatment of these diseases, various quinolones are frequently used. We determined the mutant prevention concentration (MPC) of four quinolones, levofloxacin, sitafloxacin, tosufloxacin, and garenoxacin, using 92 clinical isolates and evaluated each mutant selection window (MSW). Furthermore, the DNA sequence of the quinolone resistance-determining region (QRDR) for the resistant mutant selected based on the MSW was determined. The MIC90 and MPC90 of levofloxacin were 0.781 μg/mL and 6.250 μg/mL for S. pneumoniae and 0.049 μg/mL and 1.563 μg/mL for M. catarrhalis and were higher than those for the other three quinolones. In addition, 5 strains of 30 S. pneumoniae (16.7%) selected based on the MSW of levofloxacin acquired resistance to only levofloxacin. In these 5 strains, a mutation of gyrA and/or parC was detected. In this study, no resistant mutant was selected in the MSW of any of the other three quinolones. On the other hand, clinical isolates of H. influenzae showed no resistance by all quinolone exposure. Finally, The MIC value and the mutation status in the QRDR did not change after 14 passages in antibiotic-free medium. In conclusion, our findings suggest that the increased use of levofloxacin may contribute to the increased quinolone-resistance of S. pneumoniae and M. catarrhalis.
AB - Community-acquired pneumonia and otitis media are caused by several bacterial species, including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. For the treatment of these diseases, various quinolones are frequently used. We determined the mutant prevention concentration (MPC) of four quinolones, levofloxacin, sitafloxacin, tosufloxacin, and garenoxacin, using 92 clinical isolates and evaluated each mutant selection window (MSW). Furthermore, the DNA sequence of the quinolone resistance-determining region (QRDR) for the resistant mutant selected based on the MSW was determined. The MIC90 and MPC90 of levofloxacin were 0.781 μg/mL and 6.250 μg/mL for S. pneumoniae and 0.049 μg/mL and 1.563 μg/mL for M. catarrhalis and were higher than those for the other three quinolones. In addition, 5 strains of 30 S. pneumoniae (16.7%) selected based on the MSW of levofloxacin acquired resistance to only levofloxacin. In these 5 strains, a mutation of gyrA and/or parC was detected. In this study, no resistant mutant was selected in the MSW of any of the other three quinolones. On the other hand, clinical isolates of H. influenzae showed no resistance by all quinolone exposure. Finally, The MIC value and the mutation status in the QRDR did not change after 14 passages in antibiotic-free medium. In conclusion, our findings suggest that the increased use of levofloxacin may contribute to the increased quinolone-resistance of S. pneumoniae and M. catarrhalis.
KW - Haemophilus influenzae
KW - Moraxella catarrhalis
KW - Mutant selection window
KW - Quinolone resistance-determining region
KW - Streptococcus pneumoniae
UR - http://www.scopus.com/inward/record.url?scp=85039548560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039548560&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2017.08.009
DO - 10.1016/j.jiac.2017.08.009
M3 - Article
AN - SCOPUS:85039548560
SN - 1341-321X
VL - 24
SP - 83
EP - 87
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 2
ER -